KR20120124469A - 헤트아릴-［1,8］나프티리딘 유도체 - Google Patents

Info

Publication number

KR20120124469A

KR20120124469A KR1020127022601A KR20127022601A KR20120124469A KR 20120124469 A KR20120124469 A KR 20120124469A KR 1020127022601 A KR1020127022601 A KR 1020127022601A KR 20127022601 A KR20127022601 A KR 20127022601A KR 20120124469 A KR20120124469 A KR 20120124469A

Authority

KR

South Korea

Prior art keywords

cyy

atoms

nyy

compound

phenyl

Prior art date

2010-02-05

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 206010028980 Neoplasm Diseases 0.000 claims abstract description 43
• 238000011282 treatment Methods 0.000 claims abstract description 41
• 108090000623 proteins and genes Proteins 0.000 claims abstract description 26
• 102000004169 proteins and genes Human genes 0.000 claims abstract description 19
• 150000001875 compounds Chemical class 0.000 claims description 230
• 125000004432 carbon atom Chemical group C* 0.000 claims description 64
• 150000003839 salts Chemical class 0.000 claims description 57
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 53
• 229910052757 nitrogen Inorganic materials 0.000 claims description 48
• 238000000034 method Methods 0.000 claims description 47
• 201000010099 disease Diseases 0.000 claims description 42
• 239000004480 active ingredient Substances 0.000 claims description 37
• 125000001424 substituent group Chemical group 0.000 claims description 33
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 31
• 125000004430 oxygen atom Chemical group O* 0.000 claims description 24
• 201000011510 cancer Diseases 0.000 claims description 23
• 125000003118 aryl group Chemical group 0.000 claims description 20
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
• 239000008194 pharmaceutical composition Substances 0.000 claims description 19
• 229920006395 saturated elastomer Polymers 0.000 claims description 18
• 125000004434 sulfur atom Chemical group 0.000 claims description 17
• 108091005735 TGF-beta receptors Proteins 0.000 claims description 16
• 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims description 16
• 125000001072 heteroaryl group Chemical group 0.000 claims description 16
• 239000002253 acid Substances 0.000 claims description 15
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 15
• 230000001225 therapeutic effect Effects 0.000 claims description 14
• 230000033115 angiogenesis Effects 0.000 claims description 13
• 239000003795 chemical substances by application Substances 0.000 claims description 13
• 238000012544 monitoring process Methods 0.000 claims description 13
• 150000002148 esters Chemical class 0.000 claims description 12
• 229910052731 fluorine Inorganic materials 0.000 claims description 12
• 230000000069 prophylactic effect Effects 0.000 claims description 12
• 108091008743 testicular receptors 4 Proteins 0.000 claims description 12
• 229910052801 chlorine Inorganic materials 0.000 claims description 11
• 230000002401 inhibitory effect Effects 0.000 claims description 11
• 125000003342 alkenyl group Chemical group 0.000 claims description 9
• 229910052794 bromium Inorganic materials 0.000 claims description 9
• 208000035475 disorder Diseases 0.000 claims description 8
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
• 229910052760 oxygen Inorganic materials 0.000 claims description 8
• 230000004614 tumor growth Effects 0.000 claims description 8
• 206010016654 Fibrosis Diseases 0.000 claims description 7
• 125000000217 alkyl group Chemical group 0.000 claims description 7
• 125000000304 alkynyl group Chemical group 0.000 claims description 7
• 230000004761 fibrosis Effects 0.000 claims description 7
• 229910052717 sulfur Inorganic materials 0.000 claims description 7
• 230000029663 wound healing Effects 0.000 claims description 7
• 206010061218 Inflammation Diseases 0.000 claims description 6
• 239000002671 adjuvant Substances 0.000 claims description 6
• 210000000988 bone and bone Anatomy 0.000 claims description 6
• 210000003169 central nervous system Anatomy 0.000 claims description 6
• 230000004054 inflammatory process Effects 0.000 claims description 6
• 229910052740 iodine Inorganic materials 0.000 claims description 6
• 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 6
• 125000000169 tricyclic heterocycle group Chemical group 0.000 claims description 6
• 201000001320 Atherosclerosis Diseases 0.000 claims description 5
• 208000031886 HIV Infections Diseases 0.000 claims description 5
• 208000037357 HIV infectious disease Diseases 0.000 claims description 5
• 125000002947 alkylene group Chemical group 0.000 claims description 5
• 125000002619 bicyclic group Chemical group 0.000 claims description 5
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 5
• 238000004519 manufacturing process Methods 0.000 claims description 5
• 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 claims description 4
• 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims description 4
• 230000003412 degenerative effect Effects 0.000 claims description 4
• 230000006510 metastatic growth Effects 0.000 claims description 4
• 208000037803 restenosis Diseases 0.000 claims description 4
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 3
• 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
• 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 3
• 230000001028 anti-proliverative effect Effects 0.000 claims description 3
• 125000004429 atom Chemical group 0.000 claims description 3
• 210000000748 cardiovascular system Anatomy 0.000 claims description 3
• 239000002254 cytotoxic agent Substances 0.000 claims description 3
• 229940127089 cytotoxic agent Drugs 0.000 claims description 3
• 231100000599 cytotoxic agent Toxicity 0.000 claims description 3
• 239000002834 estrogen receptor modulator Substances 0.000 claims description 3
• 239000004030 hiv protease inhibitor Substances 0.000 claims description 3
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 3
• 201000001119 neuropathy Diseases 0.000 claims description 3
• 230000007823 neuropathy Effects 0.000 claims description 3
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
• 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims description 3
• 102000027483 retinoid hormone receptors Human genes 0.000 claims description 3
• 108091008679 retinoid hormone receptors Proteins 0.000 claims description 3
• 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 3
• 239000000849 selective androgen receptor modulator Substances 0.000 claims description 3
• 239000003558 transferase inhibitor Substances 0.000 claims description 3
• 102100028448 Nuclear receptor subfamily 2 group C member 2 Human genes 0.000 claims 1
• 239000008177 pharmaceutical agent Substances 0.000 claims 1
• 239000003112 inhibitor Substances 0.000 abstract description 15
• -1 Erk Proteins 0.000 description 155
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 93
• 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 93
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 61
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 60
• 239000011541 reaction mixture Substances 0.000 description 54
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 52
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 52
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
• 108091000080 Phosphotransferase Proteins 0.000 description 47
• 102000020233 phosphotransferase Human genes 0.000 description 47
• 230000015572 biosynthetic process Effects 0.000 description 46
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
• 239000000243 solution Substances 0.000 description 39
• 150000003254 radicals Chemical class 0.000 description 38
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 37
• 238000003786 synthesis reaction Methods 0.000 description 37
• 239000000203 mixture Substances 0.000 description 36
• 210000004027 cell Anatomy 0.000 description 34
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 33
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
• 230000000694 effects Effects 0.000 description 22
• 238000004128 high performance liquid chromatography Methods 0.000 description 22
• 230000011664 signaling Effects 0.000 description 22
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
• 239000013078 crystal Substances 0.000 description 21
• 239000003446 ligand Substances 0.000 description 21
• YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 20
• 239000012074 organic phase Substances 0.000 description 20
• 239000003480 eluent Substances 0.000 description 19
• 239000002244 precipitate Substances 0.000 description 19
• 239000002002 slurry Substances 0.000 description 19
• 229910052938 sodium sulfate Inorganic materials 0.000 description 19
• 235000011152 sodium sulphate Nutrition 0.000 description 19
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
• 239000002585 base Substances 0.000 description 18
• 238000006243 chemical reaction Methods 0.000 description 18
• 239000000741 silica gel Substances 0.000 description 18
• 229910002027 silica gel Inorganic materials 0.000 description 18
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 17
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 17
• 101001106413 Homo sapiens Macrophage-stimulating protein receptor Proteins 0.000 description 16
• 102100021435 Macrophage-stimulating protein receptor Human genes 0.000 description 16
• 230000005764 inhibitory process Effects 0.000 description 16
• 102000005962 receptors Human genes 0.000 description 16
• 108020003175 receptors Proteins 0.000 description 16
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
• 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 description 14
• 125000000623 heterocyclic group Chemical group 0.000 description 14
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 14
• 238000002360 preparation method Methods 0.000 description 14
• 230000019491 signal transduction Effects 0.000 description 14
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
• 239000000460 chlorine Substances 0.000 description 13
• 239000007787 solid Substances 0.000 description 13
• 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 12
• 230000001404 mediated effect Effects 0.000 description 12
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 11
• 239000003814 drug Substances 0.000 description 11
• 229940043355 kinase inhibitor Drugs 0.000 description 11
• 238000006366 phosphorylation reaction Methods 0.000 description 11
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 11
• FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 10
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
• 238000003556 assay Methods 0.000 description 10
• 238000009472 formulation Methods 0.000 description 10
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 10
• 239000000126 substance Substances 0.000 description 10
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
• 206010027476 Metastases Diseases 0.000 description 9
• 230000014509 gene expression Effects 0.000 description 9
• 230000009401 metastasis Effects 0.000 description 9
• 230000026731 phosphorylation Effects 0.000 description 9
• 230000001105 regulatory effect Effects 0.000 description 9
• 230000004044 response Effects 0.000 description 9
• 238000012360 testing method Methods 0.000 description 9
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 9
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 8
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
• 102000001253 Protein Kinase Human genes 0.000 description 8
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
• 230000003993 interaction Effects 0.000 description 8
• 239000000651 prodrug Substances 0.000 description 8
• 229940002612 prodrug Drugs 0.000 description 8
• 108060006633 protein kinase Proteins 0.000 description 8
• 239000002904 solvent Substances 0.000 description 8
• 239000000758 substrate Substances 0.000 description 8
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 7
• 230000018109 developmental process Effects 0.000 description 7
• 235000019253 formic acid Nutrition 0.000 description 7
• 238000000338 in vitro Methods 0.000 description 7
• 230000007246 mechanism Effects 0.000 description 7
• 239000003921 oil Substances 0.000 description 7
• 230000001575 pathological effect Effects 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• 230000035755 proliferation Effects 0.000 description 7
• 230000002829 reductive effect Effects 0.000 description 7
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
• 235000017557 sodium bicarbonate Nutrition 0.000 description 7
• 239000012453 solvate Substances 0.000 description 7
• 208000011580 syndromic disease Diseases 0.000 description 7
• 239000003826 tablet Substances 0.000 description 7
• 238000002560 therapeutic procedure Methods 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• RYVZYACBVYKUHD-UHFFFAOYSA-N Alk5 Natural products CC#CC#CCCCCC=CC(=O)NCC(C)C RYVZYACBVYKUHD-UHFFFAOYSA-N 0.000 description 6
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
• 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 6
• 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 6
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
• CAWQOMFOSDRVLD-UHFFFAOYSA-N [2-(5-chloro-2-fluorophenyl)-1,8-naphthyridin-4-yl]boronic acid Chemical compound N=1C2=NC=CC=C2C(B(O)O)=CC=1C1=CC(Cl)=CC=C1F CAWQOMFOSDRVLD-UHFFFAOYSA-N 0.000 description 6
• 230000033228 biological regulation Effects 0.000 description 6
• 239000012267 brine Substances 0.000 description 6
• 125000005488 carboaryl group Chemical group 0.000 description 6
• 125000000753 cycloalkyl group Chemical group 0.000 description 6
• 238000011161 development Methods 0.000 description 6
• 230000006870 function Effects 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 235000019198 oils Nutrition 0.000 description 6
• 239000000546 pharmaceutical excipient Substances 0.000 description 6
• 230000008569 process Effects 0.000 description 6
• 238000001959 radiotherapy Methods 0.000 description 6
• 210000003491 skin Anatomy 0.000 description 6
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
• 239000007858 starting material Substances 0.000 description 6
• 238000006467 substitution reaction Methods 0.000 description 6
• 238000010626 work up procedure Methods 0.000 description 6
• 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 5
• KNYLMSGZBZMLSJ-UHFFFAOYSA-N 4-(5-bromopyridin-3-yl)-2-(5-chloro-2-fluorophenyl)-1,8-naphthyridine Chemical compound FC1=CC=C(Cl)C=C1C1=CC(C=2C=C(Br)C=NC=2)=C(C=CC=N2)C2=N1 KNYLMSGZBZMLSJ-UHFFFAOYSA-N 0.000 description 5
• 206010006187 Breast cancer Diseases 0.000 description 5
• 208000026310 Breast neoplasm Diseases 0.000 description 5
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 5
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
• 238000001994 activation Methods 0.000 description 5
• 238000006254 arylation reaction Methods 0.000 description 5
• 210000002919 epithelial cell Anatomy 0.000 description 5
• 229910052736 halogen Inorganic materials 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 210000004072 lung Anatomy 0.000 description 5
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
• 125000002950 monocyclic group Chemical group 0.000 description 5
• 230000035772 mutation Effects 0.000 description 5
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
• 239000003208 petroleum Substances 0.000 description 5
• 125000003367 polycyclic group Chemical group 0.000 description 5
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 5
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 5
• 229910000029 sodium carbonate Inorganic materials 0.000 description 5
• 210000001519 tissue Anatomy 0.000 description 5
• 230000002792 vascular Effects 0.000 description 5
• ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 4
• AOOZLVWDZUPEHT-UHFFFAOYSA-N 3-bromo-5-iodopyridine Chemical compound BrC1=CN=CC(I)=C1 AOOZLVWDZUPEHT-UHFFFAOYSA-N 0.000 description 4
• WJNJSWJJGQDCCF-UHFFFAOYSA-N 4-chloro-2-(5-chloro-2-fluorophenyl)-1,8-naphthyridine Chemical compound FC1=CC=C(Cl)C=C1C1=CC(Cl)=C(C=CC=N2)C2=N1 WJNJSWJJGQDCCF-UHFFFAOYSA-N 0.000 description 4
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
• 102100034134 Activin receptor type-1B Human genes 0.000 description 4
• 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 4
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
• 208000005623 Carcinogenesis Diseases 0.000 description 4
• 102100037241 Endoglin Human genes 0.000 description 4
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
• 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 4
• 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 4
• 241000699670 Mus sp. Species 0.000 description 4
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
• 229910019142 PO4 Inorganic materials 0.000 description 4
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• 206010052428 Wound Diseases 0.000 description 4
• 208000027418 Wounds and injury Diseases 0.000 description 4
• 150000007513 acids Chemical class 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 230000009286 beneficial effect Effects 0.000 description 4
• 230000036952 cancer formation Effects 0.000 description 4
• 231100000504 carcinogenesis Toxicity 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 125000004122 cyclic group Chemical group 0.000 description 4
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
• 210000002889 endothelial cell Anatomy 0.000 description 4
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
• 239000000706 filtrate Substances 0.000 description 4
• 239000011737 fluorine Substances 0.000 description 4
• 210000003780 hair follicle Anatomy 0.000 description 4
• 230000002140 halogenating effect Effects 0.000 description 4
• 150000002367 halogens Chemical class 0.000 description 4
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
• 230000002757 inflammatory effect Effects 0.000 description 4
• 239000000543 intermediate Substances 0.000 description 4
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 239000002207 metabolite Substances 0.000 description 4
• 230000005012 migration Effects 0.000 description 4
• 238000013508 migration Methods 0.000 description 4
• 230000004048 modification Effects 0.000 description 4
• 238000012986 modification Methods 0.000 description 4
• 230000002018 overexpression Effects 0.000 description 4
• 235000021317 phosphate Nutrition 0.000 description 4
• IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical class CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 4
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
• 230000003389 potentiating effect Effects 0.000 description 4
• 125000003226 pyrazolyl group Chemical group 0.000 description 4
• 125000004076 pyridyl group Chemical group 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 238000010992 reflux Methods 0.000 description 4
• 230000001177 retroviral effect Effects 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• 125000004809 1-methylpropylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])C([H])([H])[*:2] 0.000 description 3
• CCQHBZIXZFQYSO-UHFFFAOYSA-N 2,4-dichloro-1,8-naphthyridine Chemical compound C1=CC=NC2=NC(Cl)=CC(Cl)=C21 CCQHBZIXZFQYSO-UHFFFAOYSA-N 0.000 description 3
• QLEPIXIMTMBVMQ-UHFFFAOYSA-N 3-bromo-5-(1-methylpyrazol-4-yl)pyridine Chemical compound C1=NN(C)C=C1C1=CN=CC(Br)=C1 QLEPIXIMTMBVMQ-UHFFFAOYSA-N 0.000 description 3
• TVOJIBGZFYMWDT-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CNN=C1 TVOJIBGZFYMWDT-UHFFFAOYSA-N 0.000 description 3
• SIADAGFXEHBPGG-UHFFFAOYSA-N 4-chloro-1,8-naphthyridine Chemical compound C1=CC=C2C(Cl)=CC=NC2=N1 SIADAGFXEHBPGG-UHFFFAOYSA-N 0.000 description 3
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 108010059616 Activins Proteins 0.000 description 3
• 102000009840 Angiopoietins Human genes 0.000 description 3
• 108010009906 Angiopoietins Proteins 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
• 201000009030 Carcinoma Diseases 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
• 206010009944 Colon cancer Diseases 0.000 description 3
• 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 3
• 108010036395 Endoglin Proteins 0.000 description 3
• 102000050554 Eph Family Receptors Human genes 0.000 description 3
• 108091008815 Eph receptors Proteins 0.000 description 3
• 102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 3
• 102100032813 Hepatocyte growth factor-like protein Human genes 0.000 description 3
• 101001066435 Homo sapiens Hepatocyte growth factor-like protein Proteins 0.000 description 3
• 101000609532 Homo sapiens Phosphoinositide-3-kinase-interacting protein 1 Proteins 0.000 description 3
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
• 102100026818 Inhibin beta E chain Human genes 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
• 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 3
• 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 3
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 108091005682 Receptor kinases Proteins 0.000 description 3
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• 239000013543 active substance Substances 0.000 description 3
• 239000000488 activin Substances 0.000 description 3
• 239000002246 antineoplastic agent Substances 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 201000008275 breast carcinoma Diseases 0.000 description 3
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
• 229910000024 caesium carbonate Inorganic materials 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 239000003054 catalyst Substances 0.000 description 3
• 238000006555 catalytic reaction Methods 0.000 description 3
• 230000004663 cell proliferation Effects 0.000 description 3
• 230000033077 cellular process Effects 0.000 description 3
• 230000005754 cellular signaling Effects 0.000 description 3
• 210000001072 colon Anatomy 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 230000004069 differentiation Effects 0.000 description 3
• 230000002526 effect on cardiovascular system Effects 0.000 description 3
• 239000008098 formaldehyde solution Substances 0.000 description 3
• 125000005842 heteroatom Chemical group 0.000 description 3
• 125000002883 imidazolyl group Chemical group 0.000 description 3
• 239000012442 inert solvent Substances 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• GDTOUTKTCGPAGY-UHFFFAOYSA-N isoquinolin-4-ylboronic acid Chemical compound C1=CC=C2C(B(O)O)=CN=CC2=C1 GDTOUTKTCGPAGY-UHFFFAOYSA-N 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 238000012423 maintenance Methods 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 150000007522 mineralic acids Chemical class 0.000 description 3
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
• 150000005054 naphthyridines Chemical class 0.000 description 3
• 235000001968 nicotinic acid Nutrition 0.000 description 3
• 239000011664 nicotinic acid Substances 0.000 description 3
• 150000007524 organic acids Chemical class 0.000 description 3
• 150000007530 organic bases Chemical class 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 230000036961 partial effect Effects 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 3
• 230000035790 physiological processes and functions Effects 0.000 description 3
• 125000003386 piperidinyl group Chemical group 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 108090000765 processed proteins & peptides Proteins 0.000 description 3
• 238000011321 prophylaxis Methods 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 125000000714 pyrimidinyl group Chemical group 0.000 description 3
• 238000007363 ring formation reaction Methods 0.000 description 3
• 125000006413 ring segment Chemical group 0.000 description 3
• 239000007921 spray Substances 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 230000002195 synergetic effect Effects 0.000 description 3
• 239000000454 talc Substances 0.000 description 3
• 235000012222 talc Nutrition 0.000 description 3
• 229910052623 talc Inorganic materials 0.000 description 3
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
• 230000000699 topical effect Effects 0.000 description 3
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
• 125000004306 triazinyl group Chemical group 0.000 description 3
• 210000003932 urinary bladder Anatomy 0.000 description 3
• JNLNRENRMLSKSC-UHFFFAOYSA-N 2-(2,5-difluorophenyl)-4-[5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-3-yl]-1,8-naphthyridine Chemical compound FC1=CC=C(F)C(C=2N=C3N=CC=CC3=C(C=3C=C(C=NC=3)C3=CN(N=C3)C3CCNCC3)C=2)=C1 JNLNRENRMLSKSC-UHFFFAOYSA-N 0.000 description 2
• CEKWGBPDGMBQRM-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-[5-[4-(4-methylpiperazin-1-yl)pyrimidin-2-yl]pyridin-3-yl]-1,8-naphthyridine Chemical compound C1CN(C)CCN1C1=CC=NC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=CC=2)F)=N1 CEKWGBPDGMBQRM-UHFFFAOYSA-N 0.000 description 2
• TUKWURGQYVAAMJ-UHFFFAOYSA-N 2-(4-chloro-1,8-naphthyridin-2-yl)benzamide Chemical compound NC(=O)C1=CC=CC=C1C1=CC(Cl)=C(C=CC=N2)C2=N1 TUKWURGQYVAAMJ-UHFFFAOYSA-N 0.000 description 2
• IHVLIAZTRYFGPK-UHFFFAOYSA-N 2-(4-chloro-1,8-naphthyridin-2-yl)benzonitrile Chemical compound N=1C2=NC=CC=C2C(Cl)=CC=1C1=CC=CC=C1C#N IHVLIAZTRYFGPK-UHFFFAOYSA-N 0.000 description 2
• FCKYTQUFUXOVQQ-UHFFFAOYSA-N 2-(5-chloro-2-fluorophenyl)-4-(5-phenylpyridin-3-yl)-1,8-naphthyridine Chemical compound FC1=CC=C(Cl)C=C1C1=CC(C=2C=C(C=NC=2)C=2C=CC=CC=2)=C(C=CC=N2)C2=N1 FCKYTQUFUXOVQQ-UHFFFAOYSA-N 0.000 description 2
• IDGCGUWIEHPFAV-UHFFFAOYSA-N 2-(5-chloro-2-fluorophenyl)-4-[5-(4-piperazin-1-ylphenyl)pyridin-3-yl]-1,8-naphthyridine Chemical compound FC1=CC=C(Cl)C=C1C1=CC(C=2C=C(C=NC=2)C=2C=CC(=CC=2)N2CCNCC2)=C(C=CC=N2)C2=N1 IDGCGUWIEHPFAV-UHFFFAOYSA-N 0.000 description 2
• VGJSMDSHAFUKQN-UHFFFAOYSA-N 2-(5-chloro-2-fluorophenyl)-4-[5-[4-(4-methylpiperazin-1-yl)phenyl]pyridin-3-yl]-1,8-naphthyridine Chemical compound C1CN(C)CCN1C1=CC=C(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=C(Cl)C=2)F)C=C1 VGJSMDSHAFUKQN-UHFFFAOYSA-N 0.000 description 2
• DJQRVGPXRBKZMT-UHFFFAOYSA-N 2-(5-chloro-2-fluorophenyl)-4-[5-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]pyridin-3-yl]-1,8-naphthyridine Chemical compound C1CN(C)CCN1C1=CC=C(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=C(Cl)C=2)F)C=N1 DJQRVGPXRBKZMT-UHFFFAOYSA-N 0.000 description 2
• ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
• NHCDIKVEYYUBIY-UHFFFAOYSA-N 2-[4-[5-[2-(5-chloro-2-fluorophenyl)-1,8-naphthyridin-4-yl]pyridin-3-yl]pyrazol-1-yl]ethanol Chemical compound C1=NN(CCO)C=C1C1=CN=CC(C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=C(Cl)C=2)F)=C1 NHCDIKVEYYUBIY-UHFFFAOYSA-N 0.000 description 2
• HABSXVJHFZUIQW-UHFFFAOYSA-N 3-bromo-5-(1-methylpyrazol-4-yl)-1-oxidopyridin-1-ium Chemical compound C1=NN(C)C=C1C1=CC(Br)=C[N+]([O-])=C1 HABSXVJHFZUIQW-UHFFFAOYSA-N 0.000 description 2
• 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 2
• 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 2
• 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 2
• LQIXVUQDOFUXTC-UHFFFAOYSA-N 4-[3-[4-[5-[2-(2,5-difluorophenyl)-1,8-naphthyridin-4-yl]pyridin-3-yl]pyrazol-1-yl]propyl]morpholine Chemical compound FC1=CC=C(F)C(C=2N=C3N=CC=CC3=C(C=3C=C(C=NC=3)C3=CN(CCCN4CCOCC4)N=C3)C=2)=C1 LQIXVUQDOFUXTC-UHFFFAOYSA-N 0.000 description 2
• TYPNTNMYUCVLIL-UHFFFAOYSA-N 4-bromo-2-(5-chloro-2-fluorophenyl)quinoline Chemical compound FC1=CC=C(Cl)C=C1C1=CC(Br)=C(C=CC=C2)C2=N1 TYPNTNMYUCVLIL-UHFFFAOYSA-N 0.000 description 2
• FSHTWRUAGYMCQQ-UHFFFAOYSA-N 4-chloro-2-(6-methylpyridin-2-yl)-1,8-naphthyridine Chemical compound CC1=CC=CC(C=2N=C3N=CC=CC3=C(Cl)C=2)=N1 FSHTWRUAGYMCQQ-UHFFFAOYSA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
• 102100034111 Activin receptor type-1 Human genes 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
• 101100220616 Caenorhabditis elegans chk-2 gene Proteins 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 208000032544 Cicatrix Diseases 0.000 description 2
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
• 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
• 102100023721 Ephrin-B2 Human genes 0.000 description 2
• 108010044090 Ephrin-B2 Proteins 0.000 description 2
• 241000711549 Hepacivirus C Species 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 2
• 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 2
• 101000777461 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 17 Proteins 0.000 description 2
• 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 2
• 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 2
• 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 2
• 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 2
• 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 2
• 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 2
• 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 2
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
• 150000001204 N-oxides Chemical class 0.000 description 2
• 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
• 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
• 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 2
• 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 2
• 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
• 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 2
• 101700032040 SMAD1 Proteins 0.000 description 2
• 108020004459 Small interfering RNA Proteins 0.000 description 2
• 238000006619 Stille reaction Methods 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
• 102000040945 Transcription factor Human genes 0.000 description 2
• 108091023040 Transcription factor Proteins 0.000 description 2
• 108091008605 VEGF receptors Proteins 0.000 description 2
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
• 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 150000001242 acetic acid derivatives Chemical class 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 150000001298 alcohols Chemical class 0.000 description 2
• 229910052783 alkali metal Inorganic materials 0.000 description 2
• 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
• 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 239000003708 ampul Substances 0.000 description 2
• 230000002491 angiogenic effect Effects 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 235000006708 antioxidants Nutrition 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 239000008346 aqueous phase Substances 0.000 description 2
• 150000005840 aryl radicals Chemical class 0.000 description 2
• RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
• 229910001863 barium hydroxide Inorganic materials 0.000 description 2
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
• 239000004305 biphenyl Substances 0.000 description 2
• 235000010290 biphenyl Nutrition 0.000 description 2
• SUAVNZMIOODRBR-UHFFFAOYSA-N bis(trifluoromethylsulfonyloxy)boranyl trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)OB(OS(=O)(=O)C(F)(F)F)OS(=O)(=O)C(F)(F)F SUAVNZMIOODRBR-UHFFFAOYSA-N 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• 125000001246 bromo group Chemical group Br* 0.000 description 2
• YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 2
• AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
• 239000000920 calcium hydroxide Substances 0.000 description 2
• 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000022131 cell cycle Effects 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 230000004709 cell invasion Effects 0.000 description 2
• 210000003679 cervix uteri Anatomy 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 101150113535 chek1 gene Proteins 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 2
• LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
• 238000012937 correction Methods 0.000 description 2
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• 230000007850 degeneration Effects 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
• SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
• 239000012153 distilled water Substances 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 239000006196 drop Substances 0.000 description 2
• 230000013020 embryo development Effects 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 102000012803 ephrin Human genes 0.000 description 2
• 108060002566 ephrin Proteins 0.000 description 2
• 210000000981 epithelium Anatomy 0.000 description 2
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 208000030533 eye disease Diseases 0.000 description 2
• 230000003176 fibrotic effect Effects 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 238000002875 fluorescence polarization Methods 0.000 description 2
• 238000011010 flushing procedure Methods 0.000 description 2
• 239000006260 foam Substances 0.000 description 2
• 210000002337 follicle stem cell Anatomy 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 125000002541 furyl group Chemical group 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 230000026030 halogenation Effects 0.000 description 2
• 238000005658 halogenation reaction Methods 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 239000013067 intermediate product Substances 0.000 description 2
• 230000009545 invasion Effects 0.000 description 2
• 239000011630 iodine Substances 0.000 description 2
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
• 125000002757 morpholinyl group Chemical group 0.000 description 2
• 210000000214 mouth Anatomy 0.000 description 2
• 125000001624 naphthyl group Chemical group 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 229960003512 nicotinic acid Drugs 0.000 description 2
• LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 238000000059 patterning Methods 0.000 description 2
• 235000019271 petrolatum Nutrition 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
• 125000004193 piperazinyl group Chemical group 0.000 description 2
• 229920000137 polyphosphoric acid Polymers 0.000 description 2
• 235000011056 potassium acetate Nutrition 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 2
• 229920001592 potato starch Polymers 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 2
• 125000003373 pyrazinyl group Chemical group 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 231100000241 scar Toxicity 0.000 description 2
• 230000037387 scars Effects 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 238000013207 serial dilution Methods 0.000 description 2
• 239000004055 small Interfering RNA Substances 0.000 description 2
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical compound [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 230000006641 stabilisation Effects 0.000 description 2
• 238000011105 stabilization Methods 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• WXAGMLBBFFLVBQ-UHFFFAOYSA-N tert-butyl 4-[4-[5-[2-(5-chloro-2-fluorophenyl)-1,8-naphthyridin-4-yl]pyridin-3-yl]pyrazol-1-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1N=CC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=C(Cl)C=2)F)=C1 WXAGMLBBFFLVBQ-UHFFFAOYSA-N 0.000 description 2
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
• URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
• 125000001425 triazolyl group Chemical group 0.000 description 2
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• 230000034512 ubiquitination Effects 0.000 description 2
• 238000010798 ubiquitination Methods 0.000 description 2
• 241001430294 unidentified retrovirus Species 0.000 description 2
• 229910052725 zinc Inorganic materials 0.000 description 2
• 239000011701 zinc Substances 0.000 description 2
• LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical class CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
• NPLZNDDFVCGRAG-UHFFFAOYSA-N (2-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1C#N NPLZNDDFVCGRAG-UHFFFAOYSA-N 0.000 description 1
• FVWWKNZKPWWOCF-UHFFFAOYSA-N (5-phenylpyridin-3-yl)boronic acid Chemical compound OB(O)C1=CN=CC(C=2C=CC=CC=2)=C1 FVWWKNZKPWWOCF-UHFFFAOYSA-N 0.000 description 1
• YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
• 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
• RPLJSSDJIXBJBD-ONEGZZNKSA-N (e)-4-[4-[5-[2-(2-fluorophenyl)-1,8-naphthyridin-4-yl]pyridin-3-yl]pyrazol-1-yl]but-2-en-1-ol Chemical compound C1=NN(C/C=C/CO)C=C1C1=CN=CC(C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=CC=2)F)=C1 RPLJSSDJIXBJBD-ONEGZZNKSA-N 0.000 description 1
• 0 *c1cc(-c(cc(cc2)Cl)c2F)nc2c1cccn2 Chemical compound *c1cc(-c(cc(cc2)Cl)c2F)nc2c1cccn2 0.000 description 1
• 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
• BNVLGAQNNFJKHG-UHFFFAOYSA-N 1-(2-aminopyridin-3-yl)ethanone Chemical compound CC(=O)C1=CC=CN=C1N BNVLGAQNNFJKHG-UHFFFAOYSA-N 0.000 description 1
• FSNGFFWICFYWQC-UHFFFAOYSA-N 1-(2-chloroethyl)pyrrolidine;hydron;chloride Chemical compound Cl.ClCCN1CCCC1 FSNGFFWICFYWQC-UHFFFAOYSA-N 0.000 description 1
• YWRBLSYOLXMZGA-UHFFFAOYSA-N 1-[2-(oxan-2-yloxy)ethyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CCOC2OCCCC2)N=C1 YWRBLSYOLXMZGA-UHFFFAOYSA-N 0.000 description 1
• 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
• 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004827 1-ethylpropylene group Chemical group [H]C([H])([H])C([H])([H])C([H])([*:1])C([H])([H])C([H])([H])[*:2] 0.000 description 1
• PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
• UCNGGGYMLHAMJG-UHFFFAOYSA-N 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C1=NN(C)C=C1B1OC(C)(C)C(C)(C)O1 UCNGGGYMLHAMJG-UHFFFAOYSA-N 0.000 description 1
• PRLTVODJPCFDHW-UHFFFAOYSA-N 1-methyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]piperidine Chemical compound C1CN(C)CCC1N1N=CC(B2OC(C)(C)C(C)(C)O2)=C1 PRLTVODJPCFDHW-UHFFFAOYSA-N 0.000 description 1
• 125000004818 1-methylbutylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
• 125000004837 1-methylpentylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
• 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
• NQUIRWXTTAMWIU-UHFFFAOYSA-N 1h-1,8-naphthyridin-4-one Chemical compound C1=CC=C2C(O)=CC=NC2=N1 NQUIRWXTTAMWIU-UHFFFAOYSA-N 0.000 description 1
• IYPFQEMKOBRMII-UHFFFAOYSA-N 1h-1,8-naphthyridine-2,4-dione Chemical compound C1=CN=C2NC(=O)CC(=O)C2=C1 IYPFQEMKOBRMII-UHFFFAOYSA-N 0.000 description 1
• XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
• LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
• 125000004825 2,2-dimethylpropylene group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[*:1])C([H])([H])[*:2] 0.000 description 1
• HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
• 125000005808 2,4,6-trimethoxyphenyl group Chemical group [H][#6]-1=[#6](-[#8]C([H])([H])[H])-[#6](-*)=[#6](-[#8]C([H])([H])[H])-[#6]([H])=[#6]-1-[#8]C([H])([H])[H] 0.000 description 1
• NIFORZSTQWZJEB-UHFFFAOYSA-N 2,4-dioxo-4a,5,6,7-tetrahydro-1H-1,8-naphthyridine-3-carboxylic acid Chemical class N1C(C(C(C2CCCN=C12)=O)C(=O)O)=O NIFORZSTQWZJEB-UHFFFAOYSA-N 0.000 description 1
• GCUOLJOTJRUDIZ-UHFFFAOYSA-N 2-(2-bromoethoxy)oxane Chemical compound BrCCOC1CCCCO1 GCUOLJOTJRUDIZ-UHFFFAOYSA-N 0.000 description 1
• XUNWYDXCHWIDLB-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-(2,7-naphthyridin-4-yl)-1,8-naphthyridine Chemical compound FC1=CC=CC=C1C1=CC(C=2C3=CC=NC=C3C=NC=2)=C(C=CC=N2)C2=N1 XUNWYDXCHWIDLB-UHFFFAOYSA-N 0.000 description 1
• KRUMSPHTGIPCHG-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-(5-pyrazol-1-ylpyridin-3-yl)-1,8-naphthyridine Chemical compound FC1=CC=CC=C1C1=CC(C=2C=C(C=NC=2)N2N=CC=C2)=C(C=CC=N2)C2=N1 KRUMSPHTGIPCHG-UHFFFAOYSA-N 0.000 description 1
• LWAQEVAXAYHSHV-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-[5-(1-methylpyrazol-3-yl)pyridin-3-yl]-1,8-naphthyridine Chemical compound CN1C=CC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=CC=2)F)=N1 LWAQEVAXAYHSHV-UHFFFAOYSA-N 0.000 description 1
• CZDPOROIINRDPH-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-[5-(1-methylpyrazol-4-yl)pyridin-3-yl]-1,8-naphthyridine Chemical compound C1=NN(C)C=C1C1=CN=CC(C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=CC=2)F)=C1 CZDPOROIINRDPH-UHFFFAOYSA-N 0.000 description 1
• IALHOCQRIWQYAF-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-[5-(1h-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl]-1,8-naphthyridine Chemical compound FC1=CC=CC=C1C1=CC(C=2C=C(C=NC=2)C=2C=C3C=NNC3=NC=2)=C(C=CC=N2)C2=N1 IALHOCQRIWQYAF-UHFFFAOYSA-N 0.000 description 1
• BXIZMEPXMZSFKS-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-[5-(2-methylpyrazol-3-yl)pyridin-3-yl]-1,8-naphthyridine Chemical compound CN1N=CC=C1C1=CN=CC(C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=CC=2)F)=C1 BXIZMEPXMZSFKS-UHFFFAOYSA-N 0.000 description 1
• GOFMNEGVYWWQLF-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-[5-(4-piperazin-1-ylpyrimidin-2-yl)pyridin-3-yl]-1,8-naphthyridine Chemical compound FC1=CC=CC=C1C1=CC(C=2C=C(C=NC=2)C=2N=C(C=CN=2)N2CCNCC2)=C(C=CC=N2)C2=N1 GOFMNEGVYWWQLF-UHFFFAOYSA-N 0.000 description 1
• VABXTTDGSBTVRE-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-[5-[1-(1-methylpiperidin-4-yl)triazol-4-yl]pyridin-3-yl]-1,8-naphthyridine Chemical compound C1CN(C)CCC1N1N=NC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=CC=2)F)=C1 VABXTTDGSBTVRE-UHFFFAOYSA-N 0.000 description 1
• GECGZZQYJCNRON-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-[5-[1-(1-methylpyrrolidin-3-yl)pyrazol-4-yl]pyridin-3-yl]-1,8-naphthyridine Chemical compound C1N(C)CCC1N1N=CC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=CC=2)F)=C1 GECGZZQYJCNRON-UHFFFAOYSA-N 0.000 description 1
• XGHXVBAMAZBBNB-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-[5-[1-(2-pyrazol-1-ylethyl)pyrazol-4-yl]pyridin-3-yl]-1,8-naphthyridine Chemical compound FC1=CC=CC=C1C1=CC(C=2C=C(C=NC=2)C2=CN(CCN3N=CC=C3)N=C2)=C(C=CC=N2)C2=N1 XGHXVBAMAZBBNB-UHFFFAOYSA-N 0.000 description 1
• OVSJEHZBZZRBGQ-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-[5-[1-(2-pyrrolidin-1-ylethyl)pyrazol-4-yl]pyridin-3-yl]-1,8-naphthyridine Chemical compound FC1=CC=CC=C1C1=CC(C=2C=C(C=NC=2)C2=CN(CCN3CCCC3)N=C2)=C(C=CC=N2)C2=N1 OVSJEHZBZZRBGQ-UHFFFAOYSA-N 0.000 description 1
• GECGZZQYJCNRON-OAQYLSRUSA-N 2-(2-fluorophenyl)-4-[5-[1-[(3r)-1-methylpyrrolidin-3-yl]pyrazol-4-yl]pyridin-3-yl]-1,8-naphthyridine Chemical compound C1N(C)CC[C@H]1N1N=CC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=CC=2)F)=C1 GECGZZQYJCNRON-OAQYLSRUSA-N 0.000 description 1
• GECGZZQYJCNRON-NRFANRHFSA-N 2-(2-fluorophenyl)-4-[5-[1-[(3s)-1-methylpyrrolidin-3-yl]pyrazol-4-yl]pyridin-3-yl]-1,8-naphthyridine Chemical compound C1N(C)CC[C@@H]1N1N=CC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=CC=2)F)=C1 GECGZZQYJCNRON-NRFANRHFSA-N 0.000 description 1
• ICRYJRYVQMDQQY-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-[5-[1-[1-(2-methoxyethyl)piperidin-4-yl]pyrazol-4-yl]pyridin-3-yl]-1,8-naphthyridine Chemical compound C1CN(CCOC)CCC1N1N=CC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=CC=2)F)=C1 ICRYJRYVQMDQQY-UHFFFAOYSA-N 0.000 description 1
• WJNMSZZPNNDCQD-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-[5-[1-[3-(4-methylpiperazin-1-yl)propyl]pyrazol-4-yl]pyridin-3-yl]-1,8-naphthyridine Chemical compound C1CN(C)CCN1CCCN1N=CC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=CC=2)F)=C1 WJNMSZZPNNDCQD-UHFFFAOYSA-N 0.000 description 1
• CRWSVCVMXVUHHL-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-[6-(6-piperazin-1-ylpyridin-3-yl)pyrazin-2-yl]-1,8-naphthyridine Chemical compound FC1=CC=CC=C1C1=CC(C=2N=C(C=NC=2)C=2C=NC(=CC=2)N2CCNCC2)=C(C=CC=N2)C2=N1 CRWSVCVMXVUHHL-UHFFFAOYSA-N 0.000 description 1
• KIXBJRWYWUXBPP-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-[6-[1-(1-methylpiperidin-4-yl)pyrazol-4-yl]pyrazin-2-yl]-1,8-naphthyridine Chemical compound C1CN(C)CCC1N1N=CC(C=2N=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=CC=2)F)=C1 KIXBJRWYWUXBPP-UHFFFAOYSA-N 0.000 description 1
• GJHYLHOELOCKNK-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-[6-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]pyrazin-2-yl]-1,8-naphthyridine Chemical compound C1CN(C)CCN1C1=CC=C(C=2N=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=CC=2)F)C=N1 GJHYLHOELOCKNK-UHFFFAOYSA-N 0.000 description 1
• KBMNJDKQPXWOIA-UHFFFAOYSA-N 2-(3-chlorophenyl)-4-[5-(1-methylpyrazol-4-yl)pyridin-3-yl]-1,8-naphthyridine Chemical compound C1=NN(C)C=C1C1=CN=CC(C=2C3=CC=CN=C3N=C(C=2)C=2C=C(Cl)C=CC=2)=C1 KBMNJDKQPXWOIA-UHFFFAOYSA-N 0.000 description 1
• UIIHSNXDPRYORQ-UHFFFAOYSA-N 2-(4-fluorophenyl)-4-[5-(1-methylpyrazol-4-yl)pyridin-3-yl]-1,8-naphthyridine Chemical compound C1=NN(C)C=C1C1=CN=CC(C=2C3=CC=CN=C3N=C(C=2)C=2C=CC(F)=CC=2)=C1 UIIHSNXDPRYORQ-UHFFFAOYSA-N 0.000 description 1
• UCMMEUMVUUHBGP-UHFFFAOYSA-N 2-(5-chloro-2-fluorophenyl)-4-(2-phenylpyridin-4-yl)-1,8-naphthyridine Chemical compound FC1=CC=C(Cl)C=C1C1=CC(C=2C=C(N=CC=2)C=2C=CC=CC=2)=C(C=CC=N2)C2=N1 UCMMEUMVUUHBGP-UHFFFAOYSA-N 0.000 description 1
• IKWDAKSBNHWBNW-UHFFFAOYSA-N 2-(5-chloro-2-fluorophenyl)-4-(6-chloropyrazin-2-yl)-1,8-naphthyridine Chemical compound FC1=CC=C(Cl)C=C1C1=CC(C=2N=C(Cl)C=NC=2)=C(C=CC=N2)C2=N1 IKWDAKSBNHWBNW-UHFFFAOYSA-N 0.000 description 1
• HSFPOZOLVVJNEN-UHFFFAOYSA-N 2-(5-chloro-2-fluorophenyl)-4-[5-[1-(1-ethylpiperidin-4-yl)pyrazol-4-yl]pyridin-3-yl]-1,8-naphthyridine Chemical compound C1CN(CC)CCC1N1N=CC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=C(Cl)C=2)F)=C1 HSFPOZOLVVJNEN-UHFFFAOYSA-N 0.000 description 1
• SMZZXRLROOPPFX-UHFFFAOYSA-N 2-(5-chloro-2-fluorophenyl)-4-[5-[1-(1-methylpiperidin-4-yl)triazol-4-yl]pyridin-3-yl]-1,8-naphthyridine Chemical compound C1CN(C)CCC1N1N=NC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=C(Cl)C=2)F)=C1 SMZZXRLROOPPFX-UHFFFAOYSA-N 0.000 description 1
• ONTBPMQUODDATN-UHFFFAOYSA-N 2-(5-chloro-2-fluorophenyl)-4-[5-[1-(1-methylpyrrolidin-3-yl)pyrazol-4-yl]pyridin-3-yl]-1,8-naphthyridine Chemical compound C1N(C)CCC1N1N=CC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=C(Cl)C=2)F)=C1 ONTBPMQUODDATN-UHFFFAOYSA-N 0.000 description 1
• KUUDIDFKLGFSMQ-UHFFFAOYSA-N 2-(5-chloro-2-fluorophenyl)-4-[5-[1-(2-piperazin-1-ylethyl)pyrazol-4-yl]pyridin-3-yl]-1,8-naphthyridine Chemical compound FC1=CC=C(Cl)C=C1C1=CC(C=2C=C(C=NC=2)C2=CN(CCN3CCNCC3)N=C2)=C(C=CC=N2)C2=N1 KUUDIDFKLGFSMQ-UHFFFAOYSA-N 0.000 description 1
• ONTBPMQUODDATN-OAQYLSRUSA-N 2-(5-chloro-2-fluorophenyl)-4-[5-[1-[(3r)-1-methylpyrrolidin-3-yl]pyrazol-4-yl]pyridin-3-yl]-1,8-naphthyridine Chemical compound C1N(C)CC[C@H]1N1N=CC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=C(Cl)C=2)F)=C1 ONTBPMQUODDATN-OAQYLSRUSA-N 0.000 description 1
• ONTBPMQUODDATN-NRFANRHFSA-N 2-(5-chloro-2-fluorophenyl)-4-[5-[1-[(3s)-1-methylpyrrolidin-3-yl]pyrazol-4-yl]pyridin-3-yl]-1,8-naphthyridine Chemical compound C1N(C)CC[C@@H]1N1N=CC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=C(Cl)C=2)F)=C1 ONTBPMQUODDATN-NRFANRHFSA-N 0.000 description 1
• WWRKYNFUZSEFEO-UHFFFAOYSA-N 2-(5-chloro-2-fluorophenyl)-4-[6-[1-(1-methylpiperidin-4-yl)pyrazol-4-yl]pyrazin-2-yl]-1,8-naphthyridine Chemical compound C1CN(C)CCC1N1N=CC(C=2N=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=C(Cl)C=2)F)=C1 WWRKYNFUZSEFEO-UHFFFAOYSA-N 0.000 description 1
• WCNHXFSQATVZBZ-UHFFFAOYSA-N 2-(5-chloro-2-fluorophenyl)-4-[6-[1-(2-pyrrolidin-1-ylethyl)pyrazol-4-yl]pyrazin-2-yl]-1,8-naphthyridine Chemical compound FC1=CC=C(Cl)C=C1C1=CC(C=2N=C(C=NC=2)C2=CN(CCN3CCCC3)N=C2)=C(C=CC=N2)C2=N1 WCNHXFSQATVZBZ-UHFFFAOYSA-N 0.000 description 1
• DFPCEQVYPJPHLN-UHFFFAOYSA-N 2-(5-chloro-2-fluorophenyl)-4-isoquinolin-4-yl-1,8-naphthyridine Chemical compound FC1=CC=C(Cl)C=C1C1=CC(C=2C3=CC=CC=C3C=NC=2)=C(C=CC=N2)C2=N1 DFPCEQVYPJPHLN-UHFFFAOYSA-N 0.000 description 1
• HUPNKZAOFPTFPH-UHFFFAOYSA-N 2-(5-chloro-2-fluorophenyl)-4-isoquinolin-4-ylquinoline Chemical compound FC1=CC=C(Cl)C=C1C1=CC(C=2C3=CC=CC=C3C=NC=2)=C(C=CC=C2)C2=N1 HUPNKZAOFPTFPH-UHFFFAOYSA-N 0.000 description 1
• XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical group COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
• MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
• CKIJYJVMZUJYMN-UHFFFAOYSA-N 2-[2-fluoro-5-(trifluoromethyl)phenyl]-4-[5-(1-methylpyrazol-4-yl)pyridin-3-yl]-1,8-naphthyridine Chemical compound C1=NN(C)C=C1C1=CN=CC(C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=C(C=2)C(F)(F)F)F)=C1 CKIJYJVMZUJYMN-UHFFFAOYSA-N 0.000 description 1
• MMZDEKQXHPQMAQ-UHFFFAOYSA-N 2-[2-fluoro-5-(trifluoromethyl)phenyl]-4-[5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-3-yl]-1,8-naphthyridine;dihydrochloride Chemical compound Cl.Cl.FC1=CC=C(C(F)(F)F)C=C1C1=CC(C=2C=C(C=NC=2)C2=CN(N=C2)C2CCNCC2)=C(C=CC=N2)C2=N1 MMZDEKQXHPQMAQ-UHFFFAOYSA-N 0.000 description 1
• DVMZGRZBNIHDPS-UHFFFAOYSA-N 2-[2-fluoro-5-(trifluoromethyl)phenyl]-4-[5-[1-(1-methylpiperidin-4-yl)pyrazol-4-yl]pyridin-3-yl]-1,8-naphthyridine Chemical compound C1CN(C)CCC1N1N=CC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=C(C=2)C(F)(F)F)F)=C1 DVMZGRZBNIHDPS-UHFFFAOYSA-N 0.000 description 1
• QSIRVJPQDMZQEX-UHFFFAOYSA-N 2-[2-fluoro-5-(trifluoromethyl)phenyl]-4-[5-[1-(2-pyrrolidin-1-ylethyl)pyrazol-4-yl]pyridin-3-yl]-1,8-naphthyridine Chemical compound FC1=CC=C(C(F)(F)F)C=C1C1=CC(C=2C=C(C=NC=2)C2=CN(CCN3CCCC3)N=C2)=C(C=CC=N2)C2=N1 QSIRVJPQDMZQEX-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• QLDXCKSFFJNXNX-UHFFFAOYSA-N 2-[4-[4-[5-[2-(2-fluorophenyl)-1,8-naphthyridin-4-yl]pyridin-3-yl]pyrazol-1-yl]piperidin-1-yl]ethanol Chemical compound C1CN(CCO)CCC1N1N=CC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=CC=2)F)=C1 QLDXCKSFFJNXNX-UHFFFAOYSA-N 0.000 description 1
• AARIMMNZHRRLRM-UHFFFAOYSA-N 2-[4-[4-[5-[2-(5-chloro-2-fluorophenyl)-1,8-naphthyridin-4-yl]pyridin-3-yl]pyrazol-1-yl]piperidin-1-yl]ethanol Chemical compound C1CN(CCO)CCC1N1N=CC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=C(Cl)C=2)F)=C1 AARIMMNZHRRLRM-UHFFFAOYSA-N 0.000 description 1
• JJNBKRLAYDRFAW-UHFFFAOYSA-N 2-[4-[5-[2-[2-fluoro-5-(trifluoromethyl)phenyl]-1,8-naphthyridin-4-yl]pyridin-3-yl]pyrazol-1-yl]ethanol Chemical compound C1=NN(CCO)C=C1C1=CN=CC(C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=C(C=2)C(F)(F)F)F)=C1 JJNBKRLAYDRFAW-UHFFFAOYSA-N 0.000 description 1
• SMDXICSTZXNHTF-UHFFFAOYSA-N 2-[4-[6-[2-(2-fluorophenyl)-1,8-naphthyridin-4-yl]pyrazin-2-yl]pyrazol-1-yl]ethanol Chemical compound C1=NN(CCO)C=C1C1=CN=CC(C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=CC=2)F)=N1 SMDXICSTZXNHTF-UHFFFAOYSA-N 0.000 description 1
• HEQOJEGTZCTHCF-UHFFFAOYSA-N 2-amino-1-phenylethanone Chemical compound NCC(=O)C1=CC=CC=C1 HEQOJEGTZCTHCF-UHFFFAOYSA-N 0.000 description 1
• LLKRSJVPTKFSLS-UHFFFAOYSA-N 2-bromo-5-iodopyridine Chemical compound BrC1=CC=C(I)C=N1 LLKRSJVPTKFSLS-UHFFFAOYSA-N 0.000 description 1
• 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
• 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
• 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
• BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 1
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
• 125000006026 2-methyl-1-butenyl group Chemical group 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
• 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
• 125000004819 2-methylbutylene group Chemical group [H]C([H])([H])C([H])(C([H])([H])[*:1])C([H])([H])C([H])([H])[*:2] 0.000 description 1
• 125000004838 2-methylpentylene group Chemical group [H]C([H])([H])C([H])(C([H])([H])[*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
• 125000004810 2-methylpropylene group Chemical group [H]C([H])([H])C([H])(C([H])([H])[*:2])C([H])([H])[*:1] 0.000 description 1
• 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
• 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
• JGABMVVOXLQCKZ-UHFFFAOYSA-N 2-phenyl-1h-quinolin-4-one Chemical compound N=1C2=CC=CC=C2C(O)=CC=1C1=CC=CC=C1 JGABMVVOXLQCKZ-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 125000004362 3,4,5-trichlorophenyl group Chemical group [H]C1=C(Cl)C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
• 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
• XRJFAWZFKYHIMI-UHFFFAOYSA-N 3-[2-(5-chloro-2-fluorophenyl)-1,8-naphthyridin-4-yl]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine;dihydrochloride Chemical compound Cl.Cl.NC1=NC=C(C2=CN(N=C2)C2CCNCC2)C=C1C(C1=CC=CN=C1N=1)=CC=1C1=CC(Cl)=CC=C1F XRJFAWZFKYHIMI-UHFFFAOYSA-N 0.000 description 1
• AAVDKBBOANBASG-UHFFFAOYSA-N 3-[4-[5-[2-(2,5-difluorophenyl)-1,8-naphthyridin-4-yl]pyridin-3-yl]pyrazol-1-yl]propan-1-ol Chemical compound C1=NN(CCCO)C=C1C1=CN=CC(C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=C(F)C=2)F)=C1 AAVDKBBOANBASG-UHFFFAOYSA-N 0.000 description 1
• APNRFWDHAJRBBY-UHFFFAOYSA-N 3-[4-[5-[2-(2,5-difluorophenyl)-1,8-naphthyridin-4-yl]pyridin-3-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound C1=NN(CC(O)CO)C=C1C1=CN=CC(C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=C(F)C=2)F)=C1 APNRFWDHAJRBBY-UHFFFAOYSA-N 0.000 description 1
• PUJLDFILRDMPNK-UHFFFAOYSA-N 3-[4-[5-[2-(5-chloro-2-fluorophenyl)-1,8-naphthyridin-4-yl]pyridin-3-yl]pyrazol-1-yl]-n,n-dimethylpropan-1-amine Chemical compound C1=NN(CCCN(C)C)C=C1C1=CN=CC(C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=C(Cl)C=2)F)=C1 PUJLDFILRDMPNK-UHFFFAOYSA-N 0.000 description 1
• MTYAVWZTGTYCNB-UHFFFAOYSA-N 3-[5-[2-(2-fluorophenyl)-1,8-naphthyridin-4-yl]pyridin-3-yl]-5-(4-methylpiperazin-1-yl)-1,2,4-oxadiazole Chemical compound C1CN(C)CCN1C1=NC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=CC=2)F)=NO1 MTYAVWZTGTYCNB-UHFFFAOYSA-N 0.000 description 1
• XTHNZEAIRIXDNB-UHFFFAOYSA-N 3-[5-[2-(5-chloro-2-fluorophenyl)-1,8-naphthyridin-4-yl]pyridin-3-yl]-5-(1-methylpiperidin-4-yl)-1,2,4-oxadiazole Chemical compound C1CN(C)CCC1C1=NC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=C(Cl)C=2)F)=NO1 XTHNZEAIRIXDNB-UHFFFAOYSA-N 0.000 description 1
• VSDMKQAVOKGGHK-UHFFFAOYSA-N 3-bromo-5-[1-(2-pyrrolidin-1-ylethyl)pyrazol-4-yl]pyridine Chemical compound BrC1=CN=CC(C2=CN(CCN3CCCC3)N=C2)=C1 VSDMKQAVOKGGHK-UHFFFAOYSA-N 0.000 description 1
• KYNOJKGKMGDSRV-UHFFFAOYSA-N 3-bromo-5-[2-(5-chloro-2-fluorophenyl)-1,8-naphthyridin-4-yl]pyridin-2-amine Chemical compound C1=C(Br)C(N)=NC=C1C1=CC(C=2C(=CC=C(Cl)C=2)F)=NC2=NC=CC=C12 KYNOJKGKMGDSRV-UHFFFAOYSA-N 0.000 description 1
• 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
• 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
• ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
• 125000006027 3-methyl-1-butenyl group Chemical group 0.000 description 1
• 125000004820 3-methylbutylene group Chemical group [H]C([H])([H])C([H])(C([H])([H])[*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
• 125000004839 3-methylpentylene group Chemical group [H]C([H])([H])C([H])(C([H])([H])C([H])([H])[*:1])C([H])([H])C([H])([H])[*:2] 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
• LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 1
• KBEOLKFODUELIW-UHFFFAOYSA-N 4-(2-azidoethyl)morpholine Chemical compound [N-]=[N+]=NCCN1CCOCC1 KBEOLKFODUELIW-UHFFFAOYSA-N 0.000 description 1
• LMWJMOHZHSSLAJ-UHFFFAOYSA-N 4-(5-bromopyridin-3-yl)-2-(2-fluorophenyl)-1,8-naphthyridine Chemical compound FC1=CC=CC=C1C1=CC(C=2C=C(Br)C=NC=2)=C(C=CC=N2)C2=N1 LMWJMOHZHSSLAJ-UHFFFAOYSA-N 0.000 description 1
• HWMAYVYTAGIQPM-UHFFFAOYSA-N 4-[2-(2,5-difluorophenyl)-1,8-naphthyridin-4-yl]-2,7-naphthyridin-1-amine Chemical compound C12=CC=NC=C2C(N)=NC=C1C(C1=CC=CN=C1N=1)=CC=1C1=CC(F)=CC=C1F HWMAYVYTAGIQPM-UHFFFAOYSA-N 0.000 description 1
• YSJCOMNEMMCZAM-UHFFFAOYSA-N 4-[2-(2-fluorophenyl)-1,8-naphthyridin-4-yl]-2,7-naphthyridin-1-amine Chemical compound C12=CC=NC=C2C(N)=NC=C1C(C1=CC=CN=C1N=1)=CC=1C1=CC=CC=C1F YSJCOMNEMMCZAM-UHFFFAOYSA-N 0.000 description 1
• VLFDOUAQXXAYCK-UHFFFAOYSA-N 4-[3-[4-[5-[2-(2-fluorophenyl)-1,8-naphthyridin-4-yl]pyridin-3-yl]pyrazol-1-yl]propyl]morpholine Chemical compound FC1=CC=CC=C1C1=CC(C=2C=C(C=NC=2)C2=CN(CCCN3CCOCC3)N=C2)=C(C=CC=N2)C2=N1 VLFDOUAQXXAYCK-UHFFFAOYSA-N 0.000 description 1
• HCNHDFCVZBPDQJ-UHFFFAOYSA-N 4-[4-(5-bromopyridin-3-yl)pyrazol-1-yl]piperidine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCC1N1N=CC(C=2C=C(Br)C=NC=2)=C1 HCNHDFCVZBPDQJ-UHFFFAOYSA-N 0.000 description 1
• JWNJUADYCWPFHO-UHFFFAOYSA-N 4-[5-(1-methylpyrazol-4-yl)pyridin-3-yl]-2-(2,4,5-trifluorophenyl)-1,8-naphthyridine Chemical compound C1=NN(C)C=C1C1=CN=CC(C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC(F)=C(F)C=2)F)=C1 JWNJUADYCWPFHO-UHFFFAOYSA-N 0.000 description 1
• PGEPPHPURVGMQH-UHFFFAOYSA-N 4-[5-(1-methylpyrazol-4-yl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)-1,8-naphthyridine Chemical compound CC1=CC=CC(C=2N=C3N=CC=CC3=C(C=3C=C(C=NC=3)C3=CN(C)N=C3)C=2)=N1 PGEPPHPURVGMQH-UHFFFAOYSA-N 0.000 description 1
• XGLYHSLHVDLCDZ-UHFFFAOYSA-N 4-[5-(1-methylpyrazol-4-yl)pyridin-3-yl]-2-[3-(trifluoromethyl)phenyl]-1,8-naphthyridine Chemical compound C1=NN(C)C=C1C1=CN=CC(C=2C3=CC=CN=C3N=C(C=2)C=2C=C(C=CC=2)C(F)(F)F)=C1 XGLYHSLHVDLCDZ-UHFFFAOYSA-N 0.000 description 1
• PGDVQHKRJFWXDE-UHFFFAOYSA-N 4-[5-[1-(1-methylpiperidin-4-yl)pyrazol-4-yl]pyridin-3-yl]-2-(6-methylpyridin-2-yl)-1,8-naphthyridine Chemical compound C1CN(C)CCC1N1N=CC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2N=C(C)C=CC=2)=C1 PGDVQHKRJFWXDE-UHFFFAOYSA-N 0.000 description 1
• CWLICDUYPKOWNB-UHFFFAOYSA-N 4-[5-[1-(1-methylpiperidin-4-yl)pyrazol-4-yl]pyridin-3-yl]-2-phenyl-1,8-naphthyridine Chemical compound C1CN(C)CCC1N1N=CC(C=2C=C(C=NC=2)C=2C3=CC=CN=C3N=C(C=2)C=2C=CC=CC=2)=C1 CWLICDUYPKOWNB-UHFFFAOYSA-N 0.000 description 1
• RKDPINFJLOEWNI-UHFFFAOYSA-N 4-[5-[2-(2-fluorophenyl)-1,8-naphthyridin-4-yl]pyridin-3-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=CN=CC(C=2C3=CC=CN=C3N=C(C=2)C=2C(=CC=CC=2)F)=C1 RKDPINFJLOEWNI-UHFFFAOYSA-N 0.000 description 1
• NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
• GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
• HCQHVQSQHXZRGA-UHFFFAOYSA-N 4-bromo-2-phenylpyridine Chemical compound BrC1=CC=NC(C=2C=CC=CC=2)=C1 HCQHVQSQHXZRGA-UHFFFAOYSA-N 0.000 description 1
• 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
• SUXIPCHEUMEUSV-UHFFFAOYSA-N 4-bromoquinoline Chemical compound C1=CC=C2C(Br)=CC=NC2=C1 SUXIPCHEUMEUSV-UHFFFAOYSA-N 0.000 description 1
• JFCJQSAXTPXNGO-UHFFFAOYSA-N 4-chloro-2-(2,4,5-trifluorophenyl)-1,8-naphthyridine Chemical compound C1=C(F)C(F)=CC(F)=C1C1=CC(Cl)=C(C=CC=N2)C2=N1 JFCJQSAXTPXNGO-UHFFFAOYSA-N 0.000 description 1
• LXACYMGZHCJFRE-UHFFFAOYSA-N 4-chloro-2-(2,5-difluorophenyl)-1,8-naphthyridine Chemical compound FC1=CC=C(F)C(C=2N=C3N=CC=CC3=C(Cl)C=2)=C1 LXACYMGZHCJFRE-UHFFFAOYSA-N 0.000 description 1
• WZKWIPOLSCLGLU-UHFFFAOYSA-N 4-chloro-2-(2-fluorophenyl)-1,8-naphthyridine Chemical compound FC1=CC=CC=C1C1=CC(Cl)=C(C=CC=N2)C2=N1 WZKWIPOLSCLGLU-UHFFFAOYSA-N 0.000 description 1
• XZVJQTNKZMMCBT-UHFFFAOYSA-N 4-chloro-2-(3-chlorophenyl)-1,8-naphthyridine Chemical compound ClC1=CC=CC(C=2N=C3N=CC=CC3=C(Cl)C=2)=C1 XZVJQTNKZMMCBT-UHFFFAOYSA-N 0.000 description 1
• HOYNYTRQKHBCHV-UHFFFAOYSA-N 4-chloro-2-(4-fluorophenyl)-1,8-naphthyridine Chemical compound C1=CC(F)=CC=C1C1=CC(Cl)=C(C=CC=N2)C2=N1 HOYNYTRQKHBCHV-UHFFFAOYSA-N 0.000 description 1
• PFPMYGSUANWCKG-UHFFFAOYSA-N 4-chloro-2-[2-fluoro-5-(trifluoromethoxy)phenyl]-1,8-naphthyridine Chemical compound FC1=CC=C(OC(F)(F)F)C=C1C1=CC(Cl)=C(C=CC=N2)C2=N1 PFPMYGSUANWCKG-UHFFFAOYSA-N 0.000 description 1
• KYDQATARRBDECO-UHFFFAOYSA-N 4-chloro-2-[2-fluoro-5-(trifluoromethyl)phenyl]-1,8-naphthyridine Chemical compound FC1=CC=C(C(F)(F)F)C=C1C1=CC(Cl)=C(C=CC=N2)C2=N1 KYDQATARRBDECO-UHFFFAOYSA-N 0.000 description 1
• MRFPJLFNJDOIDP-UHFFFAOYSA-N 4-chloro-2-[3-(trifluoromethyl)phenyl]-1,8-naphthyridine Chemical compound FC(F)(F)C1=CC=CC(C=2N=C3N=CC=CC3=C(Cl)C=2)=C1 MRFPJLFNJDOIDP-UHFFFAOYSA-N 0.000 description 1
• AJBAUBRIKAVPRS-UHFFFAOYSA-N 4-isoquinolin-4-yl-2-(6-methylpyridin-2-yl)-1,8-naphthyridine Chemical compound CC1=CC=CC(C=2N=C3N=CC=CC3=C(C=3C4=CC=CC=C4C=NC=3)C=2)=N1 AJBAUBRIKAVPRS-UHFFFAOYSA-N 0.000 description 1
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
• 125000004840 4-methylpentylene group Chemical group [H]C([H])([H])C([H])(C([H])([H])[*:2])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
• BPJJMJUMQALUSL-UHFFFAOYSA-N 4a,5,6,7-tetrahydro-1H-1,8-naphthyridine-2,4-dione Chemical compound N1C(CC(C2CCCN=C12)=O)=O BPJJMJUMQALUSL-UHFFFAOYSA-N 0.000 description 1
• IXYHUKXKWZXVDK-UHFFFAOYSA-N 5-[2-(2-fluorophenyl)-1,8-naphthyridin-4-yl]-2,7-naphthyridin-1-amine Chemical compound C1=NC=C2C(N)=NC=CC2=C1C(C1=CC=CN=C1N=1)=CC=1C1=CC=CC=C1F IXYHUKXKWZXVDK-UHFFFAOYSA-N 0.000 description 1
• NAEBEXMHMLDQLZ-UHFFFAOYSA-N 5-[2-(5-chloro-2-fluorophenyl)-1,8-naphthyridin-4-yl]pyridin-2-amine Chemical compound C1=NC(N)=CC=C1C1=CC(C=2C(=CC=C(Cl)C=2)F)=NC2=NC=CC=C12 NAEBEXMHMLDQLZ-UHFFFAOYSA-N 0.000 description 1
• WGOLHUGPTDEKCF-UHFFFAOYSA-N 5-bromopyridin-2-amine Chemical compound NC1=CC=C(Br)C=N1 WGOLHUGPTDEKCF-UHFFFAOYSA-N 0.000 description 1
• VWGAATKTEAKOCO-UHFFFAOYSA-N 5-chloro-2-fluorobenzoyl chloride Chemical compound FC1=CC=C(Cl)C=C1C(Cl)=O VWGAATKTEAKOCO-UHFFFAOYSA-N 0.000 description 1
• MAQAGRJURDEYDQ-UHFFFAOYSA-N 6-methylpyridine Chemical group CC1=C=CC=C[N]1 MAQAGRJURDEYDQ-UHFFFAOYSA-N 0.000 description 1
• UXYLOINHCQMHHY-UHFFFAOYSA-N 6-methylpyridine-2-carbonyl chloride Chemical compound CC1=CC=CC(C(Cl)=O)=N1 UXYLOINHCQMHHY-UHFFFAOYSA-N 0.000 description 1
• 108091007505 ADAM17 Proteins 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 102000021527 ATP binding proteins Human genes 0.000 description 1
• 108091011108 ATP binding proteins Proteins 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical class [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• ZBJJDYGJCNTNTH-UHFFFAOYSA-N Betahistine mesilate Chemical group CS(O)(=O)=O.CS(O)(=O)=O.CNCCC1=CC=CC=N1 ZBJJDYGJCNTNTH-UHFFFAOYSA-N 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 206010055113 Breast cancer metastatic Diseases 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
• MUWUBBRVLGOYLY-RALYKUJXSA-N CC(C)(C)OC(N(CC1)CCC1N/C=C(\C=N)/c1cncc(-c2cc(-c(cccc3)c3F)nc3c2cccn3)c1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N/C=C(\C=N)/c1cncc(-c2cc(-c(cccc3)c3F)nc3c2cccn3)c1)=O MUWUBBRVLGOYLY-RALYKUJXSA-N 0.000 description 1
• PNHVQBKJINJCIW-UHFFFAOYSA-N CN(CC1)CCC1[n]1ncc(-c2cncc(-c3cc(-c(cccc4)c4F)nc4c3cccn4)c2)c1 Chemical compound CN(CC1)CCC1[n]1ncc(-c2cncc(-c3cc(-c(cccc4)c4F)nc4c3cccn4)c2)c1 PNHVQBKJINJCIW-UHFFFAOYSA-N 0.000 description 1
• LSNSJCKGQREPDW-UHFFFAOYSA-N COC(CC(N)=O)=O Chemical compound COC(CC(N)=O)=O LSNSJCKGQREPDW-UHFFFAOYSA-N 0.000 description 1
• 101100407060 Caenorhabditis elegans par-6 gene Proteins 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 208000027932 Collagen disease Diseases 0.000 description 1
• 208000002330 Congenital Heart Defects Diseases 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• 230000005778 DNA damage Effects 0.000 description 1
• 231100000277 DNA damage Toxicity 0.000 description 1
• 101150096494 DYRK2 gene Proteins 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
• 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 108010055196 EphA2 Receptor Proteins 0.000 description 1
• 108010055334 EphB2 Receptor Proteins 0.000 description 1
• 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
• 102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical compound CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
• 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
• 108091008794 FGF receptors Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
• 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
• 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
• 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 101710155270 Glycerate 2-kinase Proteins 0.000 description 1
• 239000007818 Grignard reagent Substances 0.000 description 1
• 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 1
• 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
• 102000006947 Histones Human genes 0.000 description 1
• 108010033040 Histones Proteins 0.000 description 1
• 238000003692 Hiyama coupling reaction Methods 0.000 description 1
• 101001014196 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
• 101000878536 Homo sapiens Focal adhesion kinase 1 Proteins 0.000 description 1
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
• 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
• 101000573441 Homo sapiens Misshapen-like kinase 1 Proteins 0.000 description 1
• 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 1
• 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
• 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
• 101001074444 Homo sapiens Polycystin-1 Proteins 0.000 description 1
• 101000944909 Homo sapiens Ribosomal protein S6 kinase alpha-1 Proteins 0.000 description 1
• 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
• 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
• 102000004157 Hydrolases Human genes 0.000 description 1
• 108090000604 Hydrolases Proteins 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 description 1
• 101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 108010001127 Insulin Receptor Proteins 0.000 description 1
• 102100036721 Insulin receptor Human genes 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
• 108090000769 Isomerases Proteins 0.000 description 1
• 102000004195 Isomerases Human genes 0.000 description 1
• 101150009057 JAK2 gene Proteins 0.000 description 1
• 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
• 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
• 208000012659 Joint disease Diseases 0.000 description 1
• 206010023421 Kidney fibrosis Diseases 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 101150081525 LIMK1 gene Proteins 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 102000003960 Ligases Human genes 0.000 description 1
• 108090000364 Ligases Proteins 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 108010029223 MAP kinase kinase kinase 7 Proteins 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 101150100676 Map2k1 gene Proteins 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
• 102100026287 Misshapen-like kinase 1 Human genes 0.000 description 1
• 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 1
• 102100028192 Mitogen-activated protein kinase kinase kinase kinase 2 Human genes 0.000 description 1
• 101710144533 Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 description 1
• 102000005431 Molecular Chaperones Human genes 0.000 description 1
• 108010006519 Molecular Chaperones Proteins 0.000 description 1
• 102100030610 Mothers against decapentaplegic homolog 5 Human genes 0.000 description 1
• 101710143113 Mothers against decapentaplegic homolog 5 Proteins 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
• 241000282339 Mustela Species 0.000 description 1
• 108010083674 Myelin Proteins Proteins 0.000 description 1
• 102000006386 Myelin Proteins Human genes 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• ONXPDKGXOOORHB-BYPYZUCNSA-N N(5)-methyl-L-glutamine Chemical compound CNC(=O)CC[C@H](N)C(O)=O ONXPDKGXOOORHB-BYPYZUCNSA-N 0.000 description 1
• AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
• AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 238000006411 Negishi coupling reaction Methods 0.000 description 1
• 241000772415 Neovison vison Species 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 101710160107 Outer membrane protein A Proteins 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 108091008606 PDGF receptors Proteins 0.000 description 1
• 108091007960 PI3Ks Proteins 0.000 description 1
• 102000038030 PI3Ks Human genes 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 101150003085 Pdcl gene Proteins 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 1
• 102000003992 Peroxidases Human genes 0.000 description 1
• 239000004264 Petrolatum Substances 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
• 102100035194 Placenta growth factor Human genes 0.000 description 1
• 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 102000006478 Protein Phosphatase 2 Human genes 0.000 description 1
• 108010058956 Protein Phosphatase 2 Proteins 0.000 description 1
• 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
• 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
• 208000005074 Retroviridae Infections Diseases 0.000 description 1
• 102100033536 Ribosomal protein S6 kinase alpha-1 Human genes 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 1
• 201000009594 Systemic Scleroderma Diseases 0.000 description 1
• 206010042953 Systemic sclerosis Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 101150109894 TGFA gene Proteins 0.000 description 1
• 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 1
• DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
• BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 208000033781 Thyroid carcinoma Diseases 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 229940123468 Transferase inhibitor Drugs 0.000 description 1
• 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 1
• 102000014172 Transforming Growth Factor-beta Type I Receptor Human genes 0.000 description 1
• 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
• 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 1
• XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
• OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
• 238000005411 Van der Waals force Methods 0.000 description 1
• 208000032594 Vascular Remodeling Diseases 0.000 description 1
• 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• HONJPVLFWAUOFB-UHFFFAOYSA-N [2-(2,5-difluorophenyl)-1,8-naphthyridin-4-yl]boronic acid Chemical compound N=1C2=NC=CC=C2C(B(O)O)=CC=1C1=CC(F)=CC=C1F HONJPVLFWAUOFB-UHFFFAOYSA-N 0.000 description 1
• LHAGKQJCMHVRHE-UHFFFAOYSA-N [2-(2-cyanophenyl)-1,8-naphthyridin-4-yl]boronic acid Chemical compound N=1C2=NC=CC=C2C(B(O)O)=CC=1C1=CC=CC=C1C#N LHAGKQJCMHVRHE-UHFFFAOYSA-N 0.000 description 1
• IYORWNQEQQSNAD-UHFFFAOYSA-N [2-(2-fluorophenyl)-1,8-naphthyridin-4-yl]boronic acid Chemical compound N=1C2=NC=CC=C2C(B(O)O)=CC=1C1=CC=CC=C1F IYORWNQEQQSNAD-UHFFFAOYSA-N 0.000 description 1
• SUCLGFZGFMPAQC-UHFFFAOYSA-N [2-(6-methylpyridin-2-yl)-1,8-naphthyridin-4-yl]boronic acid Chemical compound CC1=CC=CC(C=2N=C3N=CC=CC3=C(B(O)O)C=2)=N1 SUCLGFZGFMPAQC-UHFFFAOYSA-N 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
• 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
• IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
• WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
• 239000012345 acetylating agent Substances 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000012042 active reagent Substances 0.000 description 1
• 125000002015 acyclic group Chemical group 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 230000001464 adherent effect Effects 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
• 238000006136 alcoholysis reaction Methods 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 125000002723 alicyclic group Chemical group 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 150000004703 alkoxides Chemical class 0.000 description 1
• 125000003545 alkoxy group Chemical group 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
• 238000010640 amide synthesis reaction Methods 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 230000003698 anagen phase Effects 0.000 description 1
• 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
• 150000001448 anilines Chemical class 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000003527 anti-angiogenesis Effects 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000003510 anti-fibrotic effect Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 150000001543 aryl boronic acids Chemical class 0.000 description 1
• 150000001500 aryl chlorides Chemical class 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 230000029777 axis specification Effects 0.000 description 1
• 239000000022 bacteriostatic agent Substances 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940050390 benzoate Drugs 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 150000003938 benzyl alcohols Chemical class 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
• 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 239000012867 bioactive agent Substances 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 230000015624 blood vessel development Effects 0.000 description 1
• 150000001638 boron Chemical class 0.000 description 1
• 229910052796 boron Inorganic materials 0.000 description 1
• 150000001642 boronic acid derivatives Chemical class 0.000 description 1
• 125000005620 boronic acid group Chemical group 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 125000005997 bromomethyl group Chemical group 0.000 description 1
• 210000000621 bronchi Anatomy 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 229910052792 caesium Inorganic materials 0.000 description 1
• TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
• 235000013877 carbamide Nutrition 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000006369 cell cycle progression Effects 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000009087 cell motility Effects 0.000 description 1
• 210000003855 cell nucleus Anatomy 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 150000005829 chemical entities Chemical class 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 239000007806 chemical reaction intermediate Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
• KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 208000028831 congenital heart disease Diseases 0.000 description 1
• 208000018631 connective tissue disease Diseases 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 239000012043 crude product Substances 0.000 description 1
• 238000003235 crystal violet staining Methods 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 238000011461 current therapy Methods 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 230000037416 cystogenesis Effects 0.000 description 1
• 238000006114 decarboxylation reaction Methods 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 230000030609 dephosphorylation Effects 0.000 description 1
• 238000006209 dephosphorylation reaction Methods 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000001687 destabilization Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 150000004683 dihydrates Chemical class 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
• 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 229940043264 dodecyl sulfate Drugs 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 238000011143 downstream manufacturing Methods 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• 230000032050 esterification Effects 0.000 description 1
• 238000005886 esterification reaction Methods 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 230000000893 fibroproliferative effect Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 238000003818 flash chromatography Methods 0.000 description 1
• 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 229940044627 gamma-interferon Drugs 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000012239 gene modification Methods 0.000 description 1
• 230000009395 genetic defect Effects 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 230000005017 genetic modification Effects 0.000 description 1
• 235000013617 genetically modified food Nutrition 0.000 description 1
• 230000035784 germination Effects 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 235000013773 glyceryl triacetate Nutrition 0.000 description 1
• 150000004795 grignard reagents Chemical class 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 230000009036 growth inhibition Effects 0.000 description 1
• 230000031774 hair cycle Effects 0.000 description 1
• 125000001188 haloalkyl group Chemical group 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 125000006038 hexenyl group Chemical group 0.000 description 1
• 125000005980 hexynyl group Chemical group 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
• 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
• 238000005984 hydrogenation reaction Methods 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 239000003978 infusion fluid Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 239000004026 insulin derivative Substances 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
• 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 239000000644 isotonic solution Substances 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 230000029411 keratinocyte apoptotic process Effects 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 238000000021 kinase assay Methods 0.000 description 1
• 229940099584 lactobionate Drugs 0.000 description 1
• JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
• 210000000867 larynx Anatomy 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 108020001756 ligand binding domains Proteins 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 201000005249 lung adenocarcinoma Diseases 0.000 description 1
• 230000035168 lymphangiogenesis Effects 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 210000001365 lymphatic vessel Anatomy 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
• 108010053292 macrophage stimulating protein Proteins 0.000 description 1
• 102000049853 macrophage stimulating protein Human genes 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• FODOUIXGKGNSMR-UHFFFAOYSA-L magnesium;2-oxidooxycarbonylbenzoate;hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[O-]OC(=O)C1=CC=CC=C1C([O-])=O FODOUIXGKGNSMR-UHFFFAOYSA-L 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 150000002690 malonic acid derivatives Chemical class 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 210000003716 mesoderm Anatomy 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910044991 metal oxide Inorganic materials 0.000 description 1
• 150000004706 metal oxides Chemical class 0.000 description 1
• 125000005341 metaphosphate group Chemical group 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• MGIYCRUAYQQSNL-UHFFFAOYSA-N methyl 2-bromo-4-methoxybenzoate Chemical compound COC(=O)C1=CC=C(OC)C=C1Br MGIYCRUAYQQSNL-UHFFFAOYSA-N 0.000 description 1
• 229940095102 methyl benzoate Drugs 0.000 description 1
• 210000000274 microglia Anatomy 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• 230000003990 molecular pathway Effects 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• GIOSUODMPCUDON-UHFFFAOYSA-N n-(3-acetylpyridin-2-yl)-6-methylpyridine-2-carboxamide Chemical compound CC(=O)C1=CC=CN=C1NC(=O)C1=CC=CC(C)=N1 GIOSUODMPCUDON-UHFFFAOYSA-N 0.000 description 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
• DVZIWYPXHPZUEI-UHFFFAOYSA-N n-[4-[2-(2-fluorophenyl)-1,8-naphthyridin-4-yl]-2,7-naphthyridin-1-yl]acetamide Chemical compound C12=CC=NC=C2C(NC(=O)C)=NC=C1C(C1=CC=CN=C1N=1)=CC=1C1=CC=CC=C1F DVZIWYPXHPZUEI-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
• 210000003928 nasal cavity Anatomy 0.000 description 1
• 210000003739 neck Anatomy 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• 150000002825 nitriles Chemical class 0.000 description 1
• 150000002828 nitro derivatives Chemical class 0.000 description 1
• LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
• 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 229940049964 oleate Drugs 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 238000006384 oligomerization reaction Methods 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 230000005305 organ development Effects 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 150000001282 organosilanes Chemical class 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
• 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
• 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000005981 pentynyl group Chemical group 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 208000027232 peripheral nervous system disease Diseases 0.000 description 1
• 210000004303 peritoneum Anatomy 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
• 229940066842 petrolatum Drugs 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 210000003800 pharynx Anatomy 0.000 description 1
• 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
• 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
• 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
• 229940049953 phenylacetate Drugs 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 230000000865 phosphorylative effect Effects 0.000 description 1
• 125000005498 phthalate group Chemical class 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical class OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 description 1
• 108010056274 polo-like kinase 1 Proteins 0.000 description 1
• 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 231100000127 postnatal defect Toxicity 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
• 229910000027 potassium carbonate Inorganic materials 0.000 description 1
• 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 238000002953 preparative HPLC Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000007112 pro inflammatory response Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 208000017497 prostate disease Diseases 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 230000009325 pulmonary function Effects 0.000 description 1
• 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 229940075993 receptor modulator Drugs 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 230000001172 regenerating effect Effects 0.000 description 1
• 230000029892 regulation of protein phosphorylation Effects 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 230000028617 response to DNA damage stimulus Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 238000007127 saponification reaction Methods 0.000 description 1
• 229930182490 saponin Natural products 0.000 description 1
• 150000007949 saponins Chemical class 0.000 description 1
• 235000017709 saponins Nutrition 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 238000002821 scintillation proximity assay Methods 0.000 description 1
• DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
• 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 210000001626 skin fibroblast Anatomy 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 239000011343 solid material Substances 0.000 description 1
• 238000000638 solvent extraction Methods 0.000 description 1
• 239000008347 soybean phospholipid Substances 0.000 description 1
• 125000003003 spiro group Chemical group 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 229940031439 squalene Drugs 0.000 description 1
• TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 210000002536 stromal cell Anatomy 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 229940086735 succinate Drugs 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 150000003462 sulfoxides Chemical class 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 150000003892 tartrate salts Chemical class 0.000 description 1
• QSQWENQPOSRWLP-UHFFFAOYSA-N tert-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1N=CC(B2OC(C)(C)C(C)(C)O2)=C1 QSQWENQPOSRWLP-UHFFFAOYSA-N 0.000 description 1
• DCQGWRXQFFUGBZ-UHFFFAOYSA-N tert-butyl 4-[4-(5-bromopyridin-3-yl)pyrazol-1-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1N=CC(C=2C=C(Br)C=NC=2)=C1 DCQGWRXQFFUGBZ-UHFFFAOYSA-N 0.000 description 1
• CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
• 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 125000001984 thiazolidinyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 1
• RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical compound C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 description 1
• 229940125670 thienopyridine Drugs 0.000 description 1
• 239000002175 thienopyridine Substances 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000023750 transforming growth factor beta production Effects 0.000 description 1
• 102000052185 transforming growth factor beta receptor activity proteins Human genes 0.000 description 1
• 108700015056 transforming growth factor beta receptor activity proteins Proteins 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 229960002622 triacetin Drugs 0.000 description 1
• FWSPXZXVNVQHIF-UHFFFAOYSA-N triethyl(ethynyl)silane Chemical group CC[Si](CC)(CC)C#C FWSPXZXVNVQHIF-UHFFFAOYSA-N 0.000 description 1
• VHKIEYIESYMHPT-UHFFFAOYSA-N triethyl(methoxycarbonylsulfamoyl)azanium;hydroxide Chemical compound [OH-].CC[N+](CC)(CC)S(=O)(=O)NC(=O)OC VHKIEYIESYMHPT-UHFFFAOYSA-N 0.000 description 1
• 150000004684 trihydrates Chemical class 0.000 description 1
• KPZYAGQLBFUTMA-UHFFFAOYSA-K tripotassium;phosphate;trihydrate Chemical compound O.O.O.[K+].[K+].[K+].[O-]P([O-])([O-])=O KPZYAGQLBFUTMA-UHFFFAOYSA-K 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 239000000717 tumor promoter Substances 0.000 description 1
• 230000002100 tumorsuppressive effect Effects 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 150000003672 ureas Chemical class 0.000 description 1
• 210000002229 urogenital system Anatomy 0.000 description 1
• 238000002255 vaccination Methods 0.000 description 1
• 230000007556 vascular defect Effects 0.000 description 1
• 230000004218 vascular function Effects 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 230000007998 vessel formation Effects 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 239000008096 xylene Substances 0.000 description 1